Status:
COMPLETED
An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis
Lead Sponsor:
Amgen
Collaborating Sponsors:
Immunex Corporation
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
An open-label, single arm study to estimate the rate of failure of the Enbrel® SureClick™ Auto-injector in RA subjects.
Eligibility Criteria
Inclusion
- Diagnosis of rheumatoid arthritis
- RA subjects
- 18 years or older
- Currently taking etanercept in pre-filled syringes for at least 4 weeks
- Subjects must give written informed consent
- Subjects must be able to read and write in English
Exclusion
- Subject is not using adequate contraception
- Subject is pregnant or breast feeding
- Significant concurrent medical diseases
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT00346294
Start Date
January 1 2006
End Date
July 1 2006
Last Update
January 22 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.